Analyst firms · Wolfe Research · RGEN
Wolfe Research RGEN price target and rating history
Repligen Corporation (RGEN) · Health Care
Wolfe Research rates Repligen Corporation (RGEN) Outperform with a $145 price target, as of its latest action on Jun 2, 2026. It has published 3 rating actions on RGEN since November 2024, including 1 upgrade and 0 downgrades. Across 5 firms with a RGEN price target in the last 12 months, the median target is $160. Wolfe Research's $145 is 9% below that.
- Current rating
- Outperform
- Price target
- $145
- Median target, all firms
- $160
- Actions on RGEN
- 3
Wolfe Research price target on RGEN
Every Wolfe Research rating on RGEN
- Jun 2, 2026
- Apr 29, 2025
- Nov 14, 2024
How other firms rate RGEN
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Buy | $225 | Sep 9, 2026 |
| The Benchmark Company | Buy | $185 | Jul 7, 2026 |
| Wolfe Research | Outperform | $145 | Jun 2, 2026 |
| RBC Capital Markets | Outperform | $160 | May 15, 2026 |
| Rothschild & Co Redburn | Buy | $160 | Apr 17, 2026 |
Questions about Wolfe Research and RGEN
- What is Wolfe Research's price target for RGEN?
- Wolfe Research's latest stated price target for Repligen Corporation (RGEN) is $145, from its action on Jun 2, 2026.
- What is Wolfe Research's rating on RGEN?
- Wolfe Research rates RGEN Outperform, a bullish rating, as of Jun 2, 2026.
- When did Wolfe Research last change its view on RGEN?
- On Jun 2, 2026, Wolfe Research resumes coverage at Outperform, price target $145.
- How does Wolfe Research's RGEN target compare with other analysts?
- Across 5 firms with a RGEN price target in the last 12 months, the median target is $160. Wolfe Research's $145 is 9% below that.
More RGEN rating histories
All Wolfe Research ratingsRGEN news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.